Increased risks of second (contralateral) breast cancer diagnosis have been described for CHEK2 c.1100delC breast cancer patients [[2], [3], [4], [5],11], and could therefore have been a reason for the increased risk of recurrent disease reported previously. Here, CHEK2 is linked to breast carcinoma.